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Abstract
Background: Stereotactic body radiation therapy (SBRT) is a radiation technique used in patients with
oligometastatic lung disease. Lung and chest wall toxicities have been described in the patients but pathological
vertebral fracture is an adverse effect no reported in patients treated with SBRT for lung metastases.
Case presentation: A 68-year-old woman with the diagnosis of a recurrence of a single lung metastatic nodule of
urothelial carcinoma after third line of chemotherapy. The patient received a hypo-fractionated course of SBRT.A
3D-conformal multifield technique was used with six coplanar and one non-coplanar statics beams. A total dose of
48 Gy in three fractions over six days was prescribed to the 95% of the CTV. Ten months after the SBRT procedure,
a CT scan showed complete response of the metastatic disease without signs of radiation pneumonitis. However,
rib and vertebral bone toxicities were observed with the fracture-collapse of the 7
th and 8
th vertebral bodies and a
fracture of the 7
th and 8
th left ribs. We report a unique case of pathological vertebral fracture appearing ten
months after SBRT for an asymptomatic growing lung metastases of urothelial carcinoma.
Conclusion: Though SBRT allows for minimization of normal tissue exposure to high radiation doses SBRT
tolerance for vertebral bone tissue has been poorly evaluated in patients with lung tumors. Oncologists should be
alert to the potential risk of fatal bone toxicity caused by this novel treatment. We recommend BMD testing in all
woman over 65 years old with clinical risk factors that could contribute to low BMD. If low BMD is demonstrated,
we should carefully restrict the maximum radiation dose in the vertebral body in order to avoid intermediate or
low radiation dose to the whole vertebral body.
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Background
Stereotactic body radiation therapy (SBRT) is a new
external radiation treatment modality that involves the
precise irradiation of extracranial tumors using very
high doses of radiation in one to five fractions. SBRT
has been used mainly to treat inoperable lung and liver
tumors, but it is also used in the treatment of oligome-
tastatic lung tumors [1]. Phase I/II data from patients
with oligometastatic lung disease who were treated with
SBRT seem to be very promising, with high rates of
local control and long-term survivors in properly
selected patients [2,3].
SBRT for metastatic lung disease can produce radiation
pneumonitis, but the reported incidence of grade 3-4
pneumonitis is low, in the range of 0-5%. Nonpulmonary
toxic effects, such as esophagitis, esophageal stenosis,
massive hemoptysis, pleural effusion and pericardial effu-
sion, are more frequently observed in centrally located
primary lung tumors when they are treated with a total
dose of 60-66 Gy (three fractions of 20 Gy). These toxic
effects have not been reported in lung metastatic tumors
that are peripherally located, and the presence of patho-
logic vertebral fractures have only been described in
patients who were treated with SBRT for metastatic
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vertebral fracture appearing 10 months after SBRT for an
asymptomatic growing lung metastasis of urothelial
carcinoma.
Case presentation
A 68-year-old woman was referred to our department in
February 2008 for a second opinion regarding a meta-
static urothelial carcinoma. Her history began six months
prior to her visit when she presented with recurrent urin-
ary tract infections. A cystoscopy and TUR revealed a
high grade infiltrating urothelial carcinoma in the lateral
right wall of the bladder (T2a). Staging CT scans were
performed and showed metastatic disease mediastinal
and hiliar lymph nodes, multiple and bilateral lung
nodules, and metastases located in the internal iliac
lymph nodes. The patient was initially treated with six
cycles of chemotherapy with gemcitabine 1200 mg/m
2 on
day 1 and 60 mg/m
2 cisplatin on days 1 and 8 every 21
days, showing a partial response after three cycles. The
disease was followed up until January 2009, when ima-
ging studies demonstrated the presence of a single meta-
static lesion in the left lower lung lobe. A second line of
chemotherapy using carboplatin AUC = 3 on day 1 and
1500 mg/m
2 gemcitabine on day 1 every 15 days was
initiated, and after eight cycles, new progression of the
described lung lesion was documented. A third line of
chemotherapy was proposed, and in June 2009, the
patient was started on cisplatin 60 mg/m
2 and peme-
trexed 500 mg/m
2 day 1 every 28 days. She had a partial
response after two cycles, and after four cycles of che-
motherapy, a slight increase in the size of the left lower
lung nodule was revealed on the CT scan, although a
bone scan was negative.
With the diagnosis of a recurrence of a single lung meta-
static nodule measuring 56 × 53 × 51 millimeters, in Octo-
ber 2009, a hypo-fractionated course of SBRT was
delivered to the lung nodule. This patient was placed in a
supine position and was immobilized using an alpha cradle
device to improve the reproducibility of the setup during
daily treatments. A planning CT scan was performed. A
combination of three sets of CT scans obtained during
free breathing, deep inspiration and deep expiration were
used to generate an internal target volume (ITV) that
accounts for respiratory motion. The gross tumor volume
(GTV) was the lung nodule, and the clinical target volume
(CTV) included the ITV with a symmetric 0.5 cm margin.
Respiratory tumor movement was observed under fluoro-
scopy. The delimited organs at risk (OARS) and the
applied constraints are listed in Figure 1.
A 3D-conformal multifield technique was used with
six coplanar and one non-coplanar statics beams. SBRT
Figure 1 Dose volume histograms showing dosimetric parameters analyzed including targets and organs at risk.
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Palo Alto, California, USA) with 6-MV photons. A total
dose of 48 Gy in three fractions over six days was pre-
scribed to the 95% of the CTV (Figure 2). Patient posi-
tioning and isocenter verification were checked using
cone beam CT.
Results
The patient continued a regular follow-up program with
history, physical examination, complete blood count,
liver and renal function tests, thorax-CT scan and bone
scan were performed at 3-month intervals. Ten months
after the SBRT procedure, a CT scan showed complete
r e s p o n s eo ft h em e t a s t a t i cd i s e a s ew i t h o u ts i g n so f
radiation pneumonitis and segmental atelectasis. How-
ever, rib and vertebral bone toxicities were observed
with the fracture-collapse of the 7
th and 8
th vertebral
bodies and a fracture of the 7
th-8
th left ribs. Magnetic
resonance imaging (MRI) of the spine was performed
and showed vertebral collapse in the top plate of the 7
th
and 8
th vertebral bodies with anterior wedging signs and
bone edema in the left pedicle. There was no associated
soft tissue mass, spinal cord compression or invasion of
the spinal canal. A percutaneous vertebral biopsy
showed fibrosis and no tumoral cells were discovered in
the pathologic analysis.
Reviewing the treatment plan and considering the ver-
tebral MRI, we determined that the vertebral lesion was
located marginal to the high radiation dose, noting that
the 10 Gy isodose line shaped the 7
th and 8
th vertebral
fracture (Figure 3). However, the dosimetric review
showed that the 40 Gy isodose line shapped the 7
th and
8
th rib fractures and the volume of the chest wall receiv-
ing at least 30 Gy was > 35 cc (V30). The Dmax in the
fractured ribs was 50 Gy (Figure 4).
At present, the patient continues to be asymptomatic
without any evidence of metastatic disease based on
physical examination, CT scans and spinal MR images.
However, a bone mineral density measurements for
lumbar spine (L2-L4 area) with dual energy X-ray
absorptiometry were performed and showed a low bone
mineral density (BMD) of 0,7346 gr/cm2 which was
equivalent to a T score of -3,02; therefore, our patient
was diagnosed with osteoporosis.
Discussion
SBRT delivers large doses of radiation in few fractions,
and it has been demonstrated to be a safe and effective
radiation technique for the treatment of selected
patients with lung metastases. The reported 2-year local
control ranges from 67% to 100% [4] and asymptomatic
pneumonitis is the most frequently observed grade 1-2
adverse effect. A low incidence of grade 3 pulmonary
and nonpulmonary toxicity has been reported in
patients with lung metastases treated with SBRT. The
most common nonpulmonary toxicities observed in
patients with lung metastases treated with SBRT are
skin rash and rib fracture. Nevertheless, vertebrae
Figure 2 Lung metastases in the chest CT scan (A and B) before SBRT. SBRT dose distribution (C) and CT scan six months after SBRT in
which complete response of metastatic disease is demonstrated.
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SBRT for spinal tumors[5-8].
Rib fractures can be asymptomatic, and therefore,
this finding can be under-reported. Most of the studies
with SBRT in lung cancer have related the risk of rib
fracture when the volume of chest wall receiving at
least 30 Gy (V30) is > 35 cc. A recent combined analy-
sis of patients treated with thoracic SBRT from the
University of Virginia and Colorado revealed that the
V30 was the best predictor of chest wall toxicity [9].
Our patient presented with asymptomatic rib fractures.
Then V30, V40 and Dmax of the fractured ribs were <
35 cc (19 cc), 11 cc and 50 Gy, respectively. However,
the largest study reported in the literature related to
rib toxicity has been published by Andolino in 2011
[10]. This study concluded that to minimize toxicity
when treating lesions in close proximity to the chest
wall, the Dmax of the chest wall and/or ribs should be
< 50 Gy, and < 5 cc of the chest wall should receive
≥ 40 Gy.
Figure 3 Sagital view of CT slide before SBRT (A). Transverse (B) and coronal (C) view of SBRT dose distribution in the lung metastases. Blue,
yellow, and pink lines represent the 10 Gy, 20 Gy and 30 Gy isodose lines, respectively. The 10 Gy isodose distribution shapped the 7
th-8
th
vertebral fractures. (D) Sagittal and coronal (E) view of MRI ten moths before SBRT.
Figure 4 Radiation dose distribution in the transverse plane (A) and radiation dose distribution co-registered with CT images during
the follow-up (B).
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after radiation therapy. Pathologic vertebral fracture has
not been described in patients treated with SBRT for
lung metastases. SBRT on the spine can result in patho-
logic vertebral fractures, especially when at least 20% of
the vertebral body demonstrates metastatic involvement
at the time of treatment and when the lesion is lytic [6].
The use of high-dose single-fraction SBRT in patients
with spinal metastases has also resulted in a significant
rate of new or progressive vertebral compression. In a
recent study from Memorial Sloan-Kettering Cancer
Center, fracture progression occurred in 27 (39%) of 71
vertebrae treated with single dose SBRT [11]. In fact,
the recommended SBRT vertebral bone dose-volume
constraints remain an issue that is under investigation.
In addition, our patient presented an asymptomatic 7
TH
and 8
TH vertebral body collapse ten months after SBRT,
and the 10 Gy isodose curve shaped the morphology of
the fracture. The imaging suggests that the pathologic
fracture is the result of the exposure of high radiation
dose at least in the left half of the vertebrae body. We
have reviewed the radiation dose homogeneity in the
vertebral body and the SD of the dose distribution was
5.92 Gy and the homogeneity index (D5/D95) was 3.6
Gy. It is very difficult to prove that radiation hot spots
in the vertebral body are the cause of the fracture
because no data are available in the literature regarding
the risk of vertebral fracture and the homogeneity index
in patients treated with SBRT. The present clinical
observation must take into account other associated
causes of pathological vertebral fracture. For example,
variables such as age, gender, body size, dietary calcium,
regular exercises, drug, caffeine and alcohol consump-
tion, bone density and other metabolic disturbances can
contribute to low BMD. The “Clinician’s Guide to Pre-
vention and Treatment of Osteoporosis (2010)” devel-
oped by the National Osteoporosis Foundation
recommends BMD testing in women aged 65 yrs and
older, regardless of clinical risk factors [12]. Initially,
this 68-years-old postmenopausal woman was not con-
s i d e r e dt ob eac a n d i d a t ef o raB M Dt e s tb e f o r eS B R T ;
this was, because she was evaluated clinically, had no
risk factors for osteoporosis other than age, and had
been treated with chemotherapy and corticotherapy.
After the pathologic vertebral fractures, bone mineral
density measurements for the lumbar spine (L2-L4 area)
with dual energy X-ray absorptiometry was performed
and showed a low BMD of 0.7346 gr/cm2 which was
equivalent to a T score of -3,02; therefore, our patients
was diagnosed of osteoporosis. Woman with osteoporo-
sis may be an important factor to identify patients with
high risk of severe bone toxicity after SBRT and to
minimize the risk of fractures we should be more
restrictive in the recommended constraints on the chest
wall and central structures.
In conclusion, SBRT tolerance for vertebral bone tis-
sue has been poorly evaluated in patients with lung
tumors. To the best of our knowledge, the pathologic
vertebral fracture in this patient is the first reported
using SBRT for lung metastases. Before SBRT, we
recommend BMD testing in all woman over 65 years
old with clinical risk factors that could contribute to
low BMD. If low BMD is demonstrated, we should care-
fully restrict the maximum radiation dose in the verteb-
ral body in order to avoid intermediate or low radiation
dose to the whole vertebral body. More studies are
needed to determine the radiation dose tolerance of the
vertebral body to prevent vertebral collapse in popula-
tions with clinical risk factors of pathologic fractures
such as low BMD.
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